Global Anti TIGIT Antibody Clinical Trials and Companies Insight 2023

  • No. of Pages: 100
  • Publish Date: November-2022
  • Category: Pharmaceutical and Healthcare
Electronic Access - Single User License
CD-ROM Mail Delivery
Hard Copy Mail Delivery
Electronic Access - Multi-User License

Buy USD 20,000 Worth Of Reports (Single User/Multi User License) In USD 8000 Only

Global Anti TIGIT Antibody Clinical Trials and Companies Insight 2023 Report Highlights:


  • Global Anti TIGIT Antibodies Market Dynamics
  • Insight On Anti TIGIT Antibodies Clinical Trials Insight By Phase, Company, Country, Indication
  • Anti TIGIT Antibodies In Clinical Trials : > 45
  • Overview On Partnerships and Collaborations In The Global Anti TIGIT Antibodies Market
  • Global Anti TIGIT Antibodies Market Outlook
  • Competitive Landscape


The advancement in the field of genomics has led to identification of T-cell immunoreceptor with immunoglobulin and ITIM domain (TIGIT) as a promising emerging immune checkpoint target. TIGIT indirectly suppresses T-cell activation and is expressed on multiple types of immune cells, including regulatory T (Treg) cells, activated T cells, and natural killer (NK) cells. TIGIT is up regulated in T cells and NK cells after ligand binding, inhibiting these cells’ ability to kill tumor cells. Increased TIGIT expression is also associated with advanced disease and poor survival outcomes. Additionally, increased TIGIT expression after treatment is associated with disease recurrence.


Since its identification as potential immunotherapy target, pharmaceutical companies have developed a robust pipeline of TIGIT inhibitors and are reporting promising preclinical and clinical trial results. Recently, iTeos Therapeutics has announced promising preclinical and clinical analyses supporting the multifaceted mechanism of action of its anti-TIGIT antibody, EOS-448/GSK4428859A, which is being developed in collaboration with GlaxoSmithKline. Various combinations of anti-TIGIT antibody isotopes have been studied in cancer models of mouse. Depending on the isotope used, the preclinical analyses of these combinations have demonstrated different anti-tumor activities. Strong anti-tumor activities have been found while using the isotope engaging the Fcandgamma;R, which has been linked to the activation of effector CD8 T cells and the reduction in the number of Treg cells in the tumor microenvironment. EOS-448 has further shown to induce the depletion of the precursors of exhausted T cells in addition to regulatory T cells, but not of stem-like memory T cells.


The recent years have seen an increase in collaborations and partnerships between companies for a faster development of novel drugs. Shanghai Junshi Biosciences and Coherus Bioscience recently announced that the two are taking their immuno-oncology collaboration agreement further by allowing Coherus to initiate its option to license the former’s potential anti-TIGIT antibody - JS 006 - in the US and China. Regulatory bodies of the two regions have already approved the drug’s Investigational new drug (IND) applications, allowing the companies to develop it further clinically. Apart from this, clinical trials are ongoing which are assessing the drug’s safety, pharmacokinetic properties and tolerability post dose escalation and expansion, as a monotherapy and in combination with toripalimab, an anti-PD-1 antibody, in patients with advanced solid tumors.


Apart from these trends in the market, the pipeline of novel TIGIT inhibitor is highly crowded which suggests promising future of the market. The key drugs in research and development include including AB 154, Ociperlimab, COM902, EOS448, Tiragolumab, and others. As per our analysis, TIGIT inhibitor is expected to enter the market by 2024, which will transform the overall immunotherapy market during the forecast period. However, the market will mainly be restricted by the long duration of drug development and stringent regulatory guidelines. However, as the healthcare sector of majority regions is shifting towards novel therapeutic approach the drug regulatory bodies are providing special provisions and rapid approvals are expected in coming years.


As per our report findings, the global market is expected to have opportunity of more than US$ 300 Million once the first Anti TIGIT antibody is commercially approved in coming years. The Anti TIGIT Antibody clinical development and market opportunity is driven by the rising occurrence of different forms of cancer, technological advancements in the field of immune-oncology for cancer treatment, and rising awareness concerning the benefits of targeted therapies over conventional cancer therapies. Apart from this, rising government initiatives, increasing awareness among population, and development of favorable reimbursement policies is also boosting the growth of market during the forecast period.


This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product’s mechanism of action, dosage and administration, and other development activities.

Need custom market research solution? We can help you with that too.